Zanolimumab
Human monoclonal antibody
NY (what is this?) (verify) Zanolimumab is an investigational human monoclonal antibody and an immunosuppressive drug.[1] It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma,[2] cutaneous and peripheral T-cell lymphoma.[3][4] Development of the drug was ultimately discontinued with termination of all trials.[5]
References
- ^ Mestel DS, Beyer M, Möbs M, Steinhoff M, Sterry W, Assaf C (December 2008). "Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome". Expert Opinion on Biological Therapy. 8 (12): 1929–39. doi:10.1517/14712590802528696. PMID 18990079. S2CID 58115371.
- ^ "TenX BioPharma". Archived from the original on April 11, 2010. Retrieved August 20, 2010.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab Archived 2011-06-04 at the Wayback Machine, American Medical Association.
- ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
- ^ "Status of clinical trials for Zanolimumab". Archived from the original on 27 May 2013. Retrieved 6 November 2011.
- v
- t
- e
Immunosuppressive drugs / Immunosuppressants (L04)
(initiation)
Antimetabolites |
|
---|---|
Macrolides/ other IL-2 inhibitors | |
IMiDs |
(reception)
IL-1 receptor antagonists | |
---|---|
mTOR |
Antibodies |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
-cept (Fusion) |
- Avacopan
- Baricitinib
- Bimekizumab
- Blisibimod
- Briakinumab
- Brodalumab
- Canakinumab
- Crovalimab
- Danicopan
- Darvadstrocel
- Deucravacitinib
- Deuruxolitinib
- Dimethyl fumarate
- Diroximel fumarate
- Efgartigimod alfa (+hyaluronidase)
- Etrasimod
- Filgotinib
- Fingolimod
- Guselkumab
- Iptacopan
- Itacitinib
- Ixekizumab
- Netakimab
- Olokizumab
- Ozanimod
- Peficitinib
- Pegcetacoplan
- Pirfenidone
- Ponesimod
- Ravulizumab
- Risankizumab
- Ritlecitinib
- Rozanolixizumab
- Sarilumab
- Satralizumab
- Siltuximab
- Siponimod
- Sirukumab
- Spesolimab
- Sutimlimab
- Tildrakizumab
- Tofacitinib
- Upadacitinib
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e